Acrizanib

DB16081InvestigationalSmall molecule

Acrizanib is under investigation in clinical trial NCT02355028 (LHA510 Proof-of-concept Study as a Maintenance Therapy for Patients With Wet Age-related Macular Degeneration).

Mechanism: Pharmacologically active on Vascular endothelial growth factor receptor 2 and Vascular endothelial growth factor receptor
Curator reviewed
Formula / weight: C₂₀H₁₈F₃N₇O₂ · 445.406 g/mol (avg)
Code names: LHA-510

Resolves to

Compound

UNIIF2CB8801I3CAS1229453-99-9ChEMBLCHEMBL4076112

Structure

InChIKeyXPIHPLVWOUDMPF-UHFFFAOYSA-NSMILESCNCC1=CC(OC2=CC=C3N(C=CC3=C2)C(=O)NC2=NN(C)C(=C2)C(F)(F)F)=NC=N1

Targets

P35968KDR

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Acrizanib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account